Exact Mass: 357.1927

Exact Mass Matches: 357.1927

Found 110 metabolites which its exact mass value is equals to given mass value 357.1927, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

(S)-Laudanosine

1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline

C21H27NO4 (357.194)


(S)-Laudanosine is found in opium poppy. (S)-Laudanosine is an alkaloid from Papaver somniferum (opium poppy Alkaloid from Papaver somniferum (opium poppy). (S)-Laudanosine is found in opium poppy. D002491 - Central Nervous System Agents DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity[1]. DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity[1].

   

Nalbuphine

(1S,5R,13R,14S,17S)-4-(cyclobutylmethyl)-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7,9,11(18)-triene-10,14,17-triol

C21H27NO4 (357.194)


Nalbuphine is only found in individuals that have used or taken this drug. It is a narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. [PubChem]The exact mechanism of action is unknown, but is believed to interact with an opiate receptor site in the CNS (probably in or associated with the limbic system). The opiate antagonistic effect may result from competitive inhibition at the opiate receptor, but may also be a result of other mechanisms. Nalbuphine is thought primarily to be a kappa agonist. It is also a partial mu antagonist analgesic, with some binding to the delta receptor and minimal agonist activity at the sigma receptor. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AF - Morphinan derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Proteinase inhibitor E 64

3-[[[(1S)-1-[[[4-[(aminoiminomethyl)amino]butyl]amino]carbonyl]-3-methylbutyl]amino]carbonyl]-(2S,3S)-oxiranecarboxylic acid

C15H27N5O5 (357.2012)


D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents KEIO_ID E015; [MS2] KO008950 KEIO_ID E015

   

5-hydroxypropafenone

1-{5-hydroxy-2-[2-hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one

C21H27NO4 (357.194)


5-hydroxypropafenone is a metabolite of propafenone. Propafenone is a class of anti-arrhythmic medication, which treats illnesses associated with rapid heart beats such as atrial and ventricular arrhythmias. (Wikipedia) D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents

   

(2R,3R)-3-[[(2S)-1-[4-(Diaminomethylideneamino)butylamino]-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid

(2R,3R)-3-[[(2S)-1-[4-(Diaminomethylideneamino)butylamino]-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid

C15H27N5O5 (357.2012)


   

(E)-(4-Acetoxycinnamoyl)-epilupinine

(E)-(4-Acetoxycinnamoyl)-epilupinine

C21H27NO4 (357.194)


   

Protostephanine

Protostephanine

C21H27NO4 (357.194)


   
   
   
   

JWH 018 8-quinolinyl carboxamide

JWH 018 8-quinolinyl carboxamide

C23H23N3O (357.1841)


   

N-(naphthalen-1-yl)-2-pentyl-2h-indazole-3-carboxamide

N-(naphthalen-1-yl)-2-pentyl-2h-indazole-3-carboxamide

C23H23N3O (357.1841)


   

(2S)-[(2S)-aminopropionylamino]-5-{[(3S)-((1S)-methylpropyl)-4-oxooxetane-(2R)-carbonyl]amino}pentanoic acid|belactosin C

(2S)-[(2S)-aminopropionylamino]-5-{[(3S)-((1S)-methylpropyl)-4-oxooxetane-(2R)-carbonyl]amino}pentanoic acid|belactosin C

C16H27N3O6 (357.19)


   

methyl 4-((E)-2-acetyl-4-oxonon-1-enyl)-6-((E)-prop-1-enyl)nicotinate|monascopyridine E|Monasnicotinate A

methyl 4-((E)-2-acetyl-4-oxonon-1-enyl)-6-((E)-prop-1-enyl)nicotinate|monascopyridine E|Monasnicotinate A

C21H27NO4 (357.194)


   

secocularine

secocularine

C21H27NO4 (357.194)


   

Pro Asp Leu

Pro Asp Leu

C16H27N3O6 (357.19)


   

Glu Pro Ile

Glu Pro Ile

C16H27N3O6 (357.19)


   

Pro Glu Ile

Pro Glu Ile

C16H27N3O6 (357.19)


   
   

Pro Ile Glu

Pro Ile Glu

C16H27N3O6 (357.19)


   
   

asparagylprolyllysine

asparagylprolyllysine

C15H27N5O5 (357.2012)


   

Ile Pro Glu

Ile Pro Glu

C16H27N3O6 (357.19)


   

Leu Pro Asp

Leu Pro Asp

C16H27N3O6 (357.19)


   

Pro Leu Asp

Pro Leu Asp

C16H27N3O6 (357.19)


   
   

a jasmonoyl-L-phenylalanine

a jasmonoyl-L-phenylalanine

C21H27NO4 (357.194)


   

Laudanosine

DL-LAUDANOSINE

C21H27NO4 (357.194)


D002491 - Central Nervous System Agents Annotation level-1 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.628 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.624 Acquisition and generation of the data is financially supported by the Max-Planck-Society IPB_RECORD: 2441; CONFIDENCE confident structure DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity[1]. DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity[1].

   

nalbuphine

nalbuphine

C21H27NO4 (357.194)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AF - Morphinan derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

   

5-hydroxypropafenone

5-hydroxypropafenone

C21H27NO4 (357.194)


D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents

   

Laudanoside

Laudanoside

C21H27NO4 (357.194)


Origin: Plant; Formula(Parent): C21H27NO4; Bottle Name:Laudanosine; PRIME Parent Name:Laudanosine; PRIME in-house No.:V0357; SubCategory_DNP: Isoquinoline alkaloids, Morphine alkaloids

   

Gly Gly Lys Pro

(2S)-1-[(2S)-6-amino-2-[2-(2-aminoacetamido)acetamido]hexanoyl]pyrrolidine-2-carboxylic acid

C15H27N5O5 (357.2012)


   

Gly Gly Pro Lys

(2S)-6-amino-2-{[(2S)-1-[2-(2-aminoacetamido)acetyl]pyrrolidin-2-yl]formamido}hexanoic acid

C15H27N5O5 (357.2012)


   

Gly Lys Gly Pro

(2S)-1-{2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]acetyl}pyrrolidine-2-carboxylic acid

C15H27N5O5 (357.2012)


   

Gly Lys Pro Gly

2-{[(2S)-1-[(2S)-6-amino-2-(2-aminoacetamido)hexanoyl]pyrrolidin-2-yl]formamido}acetic acid

C15H27N5O5 (357.2012)


   

Gly Pro Gly Lys

(2S)-6-amino-2-(2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}acetamido)hexanoic acid

C15H27N5O5 (357.2012)


   

Gly Pro Lys Gly

2-[(2S)-6-amino-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}hexanamido]acetic acid

C15H27N5O5 (357.2012)


   

Glu Leu Pro

Glu Leu Pro

C16H27N3O6 (357.19)


   

Leu Glu Pro

Leu Glu Pro

C16H27N3O6 (357.19)


   
   

Lys Gly Gly Pro

(2S)-1-(2-{2-[(2S)-2,6-diaminohexanamido]acetamido}acetyl)pyrrolidine-2-carboxylic acid

C15H27N5O5 (357.2012)


   

Lys Gly Pro Gly

2-{[(2S)-1-{2-[(2S)-2,6-diaminohexanamido]acetyl}pyrrolidin-2-yl]formamido}acetic acid

C15H27N5O5 (357.2012)


   

Lys Pro Gly Gly

2-(2-{[(2S)-1-[(2S)-2,6-diaminohexanoyl]pyrrolidin-2-yl]formamido}acetamido)acetic acid

C15H27N5O5 (357.2012)


   

Glu Pro Leu

Glu Pro Leu

C16H27N3O6 (357.19)


   

Leu Pro Glu

Leu Pro Glu

C16H27N3O6 (357.19)


   
   

Pro Gly Gly Lys

(2S)-6-amino-2-(2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}acetamido)hexanoic acid

C15H27N5O5 (357.2012)


   

Pro Gly Lys Gly

2-[(2S)-6-amino-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}hexanamido]acetic acid

C15H27N5O5 (357.2012)


   
   

Pro Lys Gly Gly

2-{2-[(2S)-6-amino-2-[(2S)-pyrrolidin-2-ylformamido]hexanamido]acetamido}acetic acid

C15H27N5O5 (357.2012)


   

Pro Leu Glu

Pro Leu Glu

C16H27N3O6 (357.19)


   

Pro Glu Leu

Pro Glu Leu

C16H27N3O6 (357.19)


   

Ile Glu Pro

Ile Glu Pro

C16H27N3O6 (357.19)


   
   

Glu Ile Pro

Glu Ile Pro

C16H27N3O6 (357.19)


   

butyl prop-2-enoate,prop-2-enenitrile,prop-2-enoic acid,styrene

butyl prop-2-enoate,prop-2-enenitrile,prop-2-enoic acid,styrene

C21H27NO4 (357.194)


   

Setastine

1-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]azepane

C22H28ClNO (357.1859)


C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist

   

Inorganic pyrophosphatase

Inorganic pyrophosphatase

C21H27NO4 (357.194)


   

Boc-Tyr(bzl)-Ol

Boc-Tyr(bzl)-Ol

C21H27NO4 (357.194)


   

Decarboxy Moxifloxacin

Decarboxy Moxifloxacin

C20H24FN3O2 (357.1852)


   

9-[3-(CIS-3,5-DIMETHYL-1-PIPERAZINYL)PROPYL]CARBAZOLE MONOHYDROCHLORIDE

9-[3-(CIS-3,5-DIMETHYL-1-PIPERAZINYL)PROPYL]CARBAZOLE MONOHYDROCHLORIDE

C21H28ClN3 (357.1972)


   

(R)-laudanosine

(R)-laudanosine

C21H27NO4 (357.194)


A benzylisoquinoline alkaloid that is (R)-tetrahydropapaverine in which the amino hydrogen has been replaced by a methyl group

   

N-[[(1R,2R)-3-Oxo-2-[(Z)-2-pentenyl]cyclopentan-1-yl]acetyl]-L-phenylalanine

N-[[(1R,2R)-3-Oxo-2-[(Z)-2-pentenyl]cyclopentan-1-yl]acetyl]-L-phenylalanine

C21H27NO4 (357.194)


   

N-[[(1R)-3-Oxo-2alpha-[(Z)-2-pentenyl]cyclopentane-1alpha-yl]acetyl]-L-phenylalanine

N-[[(1R)-3-Oxo-2alpha-[(Z)-2-pentenyl]cyclopentane-1alpha-yl]acetyl]-L-phenylalanine

C21H27NO4 (357.194)


   

(2S)-2-[[2-[3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetyl]amino]-3-phenylpropanoic acid

(2S)-2-[[2-[3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetyl]amino]-3-phenylpropanoic acid

C21H27NO4 (357.194)


   

1-cyclopentyl-1-[(5,8-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-3-ethylthiourea

1-cyclopentyl-1-[(5,8-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-3-ethylthiourea

C20H27N3OS (357.1875)


   

(4R,4aS,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol

(4R,4aS,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol

C21H27NO4 (357.194)


   

(4R,4aS,7S,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol

(4R,4aS,7S,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol

C21H27NO4 (357.194)


   

N-[6-(2-amino-4-fluoroanilino)-6-oxohexyl]-4-methylbenzamide

N-[6-(2-amino-4-fluoroanilino)-6-oxohexyl]-4-methylbenzamide

C20H24FN3O2 (357.1852)


   
   

2-(Phenylmethyl)-5-[4-(phenylmethyl)-1-piperidinyl]-4-oxazolecarbonitrile

2-(Phenylmethyl)-5-[4-(phenylmethyl)-1-piperidinyl]-4-oxazolecarbonitrile

C23H23N3O (357.1841)


   

6-Amino-2-methyl-8-(4-propan-2-ylphenyl)-1,3,8,8a-tetrahydroisoquinoline-5,5,7-tricarbonitrile

6-Amino-2-methyl-8-(4-propan-2-ylphenyl)-1,3,8,8a-tetrahydroisoquinoline-5,5,7-tricarbonitrile

C22H23N5 (357.1953)


   

N-[2-[[4-(2-hydroxyethylamino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]phenyl]acetamide

N-[2-[[4-(2-hydroxyethylamino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]phenyl]acetamide

C17H23N7O2 (357.1913)


   

Pro-Glu-Leu

Pro-Glu-Leu

C16H27N3O6 (357.19)


   

Pro-Leu-Glu

Pro-Leu-Glu

C16H27N3O6 (357.19)


   

Leu-Pro-Glu

Leu-Pro-Glu

C16H27N3O6 (357.19)


   

Glu-Leu-Pro

Glu-Leu-Pro

C16H27N3O6 (357.19)


   

Ile-Glu-Pro

Ile-Glu-Pro

C16H27N3O6 (357.19)


   

Ile-Pro-Glu

Ile-Pro-Glu

C16H27N3O6 (357.19)


   

Leu-Glu-Pro

Leu-Glu-Pro

C16H27N3O6 (357.19)


   
   

Pro-Ile-Glu

Pro-Ile-Glu

C16H27N3O6 (357.19)


   
   

4-[[(1R,5S)-7-[4-[(E)-2-phenylethenyl]phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]methyl]-1,3-oxazole

4-[[(1R,5S)-7-[4-[(E)-2-phenylethenyl]phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]methyl]-1,3-oxazole

C23H23N3O (357.1841)


   

Glu-Ile-Pro

Glu-Ile-Pro

C16H27N3O6 (357.19)


   

Glu-Pro-Leu

Glu-Pro-Leu

C16H27N3O6 (357.19)


   
   
   

Glu-Pro-Ile

Glu-Pro-Ile

C16H27N3O6 (357.19)


   
   

Pro-Glu-Ile

Pro-Glu-Ile

C16H27N3O6 (357.19)


   
   

Pibutidine cation

Pibutidine cation

C19H25N4O3+ (357.1927)


   

(S)-Laudanosine

(S)-Laudanosine

C21H27NO4 (357.194)


D002491 - Central Nervous System Agents

   

e-64

e-64

C15H27N5O5 (357.2012)


D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents

   

N-Methyltetrahydropapaverine

N-Methyltetrahydropapaverine

C21H27NO4 (357.194)


   
   

ST 19:4;O2;Gly

ST 19:4;O2;Gly

C21H27NO4 (357.194)


   

(1r,3r,4s,5s,8r,9s,11s,14s,17s,18r)-3,4-dihydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-dione

(1r,3r,4s,5s,8r,9s,11s,14s,17s,18r)-3,4-dihydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-dione

C21H27NO4 (357.194)


   

dimethyl(2-{4,13,14-trimethoxy-2-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-7-yl}ethyl)amine

dimethyl(2-{4,13,14-trimethoxy-2-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-7-yl}ethyl)amine

C21H27NO4 (357.194)


   

(1r)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinoline

(1r)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinoline

C21H27NO4 (357.194)


   

5-hydroxy-4-(1-hydroxy-2,4-dimethyloct-6-en-1-ylidene)-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

5-hydroxy-4-(1-hydroxy-2,4-dimethyloct-6-en-1-ylidene)-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

C21H27NO4 (357.194)


   

(2s)-2-{[(2s)-2-amino-1-hydroxypropylidene]amino}-5-({[(2r,3s)-3-[(2s)-butan-2-yl]-4-oxooxetan-2-yl](hydroxy)methylidene}amino)pentanoic acid

(2s)-2-{[(2s)-2-amino-1-hydroxypropylidene]amino}-5-({[(2r,3s)-3-[(2s)-butan-2-yl]-4-oxooxetan-2-yl](hydroxy)methylidene}amino)pentanoic acid

C16H27N3O6 (357.19)


   

(4e)-5-hydroxy-4-[(6e)-1-hydroxy-2,4-dimethyloct-6-en-1-ylidene]-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

(4e)-5-hydroxy-4-[(6e)-1-hydroxy-2,4-dimethyloct-6-en-1-ylidene]-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

C21H27NO4 (357.194)


   

methyl 4-(2-acetyl-4-oxonon-1-en-1-yl)-6-(prop-1-en-1-yl)pyridine-3-carboxylate

methyl 4-(2-acetyl-4-oxonon-1-en-1-yl)-6-(prop-1-en-1-yl)pyridine-3-carboxylate

C21H27NO4 (357.194)


   

(1r,3r,4s,5r,8r,9s,11s,14r,17s,18r)-3,4-dihydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-dione

(1r,3r,4s,5r,8r,9s,11s,14r,17s,18r)-3,4-dihydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-dione

C21H27NO4 (357.194)


   

2-[(2-amino-1-hydroxypropylidene)amino]-5-({hydroxy[4-oxo-3-(sec-butyl)oxetan-2-yl]methylidene}amino)pentanoic acid

2-[(2-amino-1-hydroxypropylidene)amino]-5-({hydroxy[4-oxo-3-(sec-butyl)oxetan-2-yl]methylidene}amino)pentanoic acid

C16H27N3O6 (357.19)


   

(1s,9ar)-octahydro-1h-quinolizin-1-ylmethyl (2e)-3-[4-(acetyloxy)phenyl]prop-2-enoate

(1s,9ar)-octahydro-1h-quinolizin-1-ylmethyl (2e)-3-[4-(acetyloxy)phenyl]prop-2-enoate

C21H27NO4 (357.194)


   

methyl 4-[(1e)-2-acetyl-4-oxonon-1-en-1-yl]-6-[(1e)-prop-1-en-1-yl]pyridine-3-carboxylate

methyl 4-[(1e)-2-acetyl-4-oxonon-1-en-1-yl]-6-[(1e)-prop-1-en-1-yl]pyridine-3-carboxylate

C21H27NO4 (357.194)


   

(1r,3r,4s,5s,8r,9s,11s,17s,18r)-3,4-dihydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-dione

(1r,3r,4s,5s,8r,9s,11s,17s,18r)-3,4-dihydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-dione

C21H27NO4 (357.194)